GSK shares fall 5.5% despite revenue growth — The Guardian
GSK shares fell 5.5% on Oct 28 despite a 5% revenue increase to £8.9B. Profit declined 19% due to weaker vaccine sales, restructuring costs, and outlook concerns. Vaccine sales dropped 2%, with Shingrix down 5% and Arexvy down 24%. Restructuring costs total £2.4B, with £318M in Q3. GSK confirmed its annual forecast and aims for £40B+ revenue by 2031.
How this was made
The 30-second read
Why it matters
The earnings miss triggered a 5.5% intraday drop, highlighting investor concerns over vaccine outlook and cost structure.
Market read
GSK's earnings surprise and vaccine sales decline caused immediate price pressure, affecting the FTSE 100 and pharma sector sentiment.
What to watch
Potential upside from growth in HIV, cancer and lupus medicines may offset vaccine weakness.
Background
GSK released its third‑quarter results, showing a profit decline but revenue growth, with notable weakness in vaccine sales and sizable restructuring expenses.
Ticker impact
Shares fell 5.5% after GSK reported Q3 profit down 19% and weaker vaccine sales, prompting investor concern.
likely further downside as investors price in lower vaccine revenue and restructuring costs
Profit decline, vaccine sales drop, and large restructuring spend are fresh negative catalysts for a large-cap pharma.
Market effects
May weigh on broader pharma and vaccine developers as investors reassess vaccine pipelines.
Could dampen UK market sentiment, especially FTSE 100 constituents.
Limited to GSK and peers; no immediate global macro impact.
Counterpoint
If restructuring leads to long‑term cost savings, the stock could rebound on the back of higher margins.
Key entities
- companyGSK
British multinational pharmaceutical company.
